CAMP4 Therapeutics, a clinical-stage biotech developing RNA-based therapies to target genetic diseases, filed on Friday with the SEC to raise up to $75 million in an initial public offering.The company is developing regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic…
Read More…
CAMP IPO News – Genetic disease biotech CAMP4 Therapeutics files for a $75 million IPO
